Ganeshkumar Arumugam, Muthuselvam Manickam, Lima Patricia Michelle Nagai de, Rajaram Rajendren, Junqueira Juliana Campos
Department of Biosciences and Oral Diagnosis, Institute of Science and Technology, São Paulo State University (UNESP), São José dos Campos 12245-000, SP, Brazil.
Department of Materials Physics, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMTS), Chennai 602105, Tamil Nadu, India.
J Fungi (Basel). 2024 Jun 6;10(6):408. doi: 10.3390/jof10060408.
is an emerging sp. that has rapidly spread all over the world. The evidence regarding its origin and emerging resistance is still unclear. The severe infection caused by this species results in significant mortality and morbidity among the elderly and immunocompromised individuals. The development of drug resistance is the major factor associated with the therapeutic failure of existing antifungal agents. Previous studies have addressed the antifungal resistance profile and drug discovery for . However, complete coverage of this information in a single investigation is not yet available. In this review, we have mainly focused on recent developments in therapeutic strategies against . Based on the available information, several different approaches were discussed, including existing antifungal drugs, chemical compounds, essential oils, natural products, antifungal peptides, immunotherapy, antimicrobial photodynamic therapy, drug repurposing, and drug delivery systems. Among them, synthetic chemicals, natural products, and antifungal peptides are the prime contributors. However, a limited number of resources are available to prove the efficiency of these potential therapies in clinical usage. Therefore, we anticipate that the findings gathered in this review will encourage further in vivo studies and clinical trials.
是一种新兴的物种,已迅速在全球传播。关于其起源和新出现的耐药性的证据仍不清楚。该物种引起的严重感染在老年人和免疫功能低下的个体中导致显著的死亡率和发病率。耐药性的发展是现有抗真菌药物治疗失败的主要相关因素。先前的研究已经探讨了该物种的抗真菌耐药性概况和药物发现。然而,在一项单一研究中尚未能完全涵盖这些信息。在本综述中,我们主要关注针对该物种的治疗策略的最新进展。基于现有信息,讨论了几种不同的方法,包括现有的抗真菌药物、化合物、精油、天然产物、抗真菌肽、免疫疗法、抗菌光动力疗法、药物再利用和药物递送系统。其中,合成化学品、天然产物和抗真菌肽是主要贡献者。然而,用于证明这些潜在疗法在临床应用中有效性的资源有限。因此,我们预计本综述中收集的研究结果将鼓励进一步的体内研究和临床试验。